|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC10A7 |
Gene summary for SLC10A7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC10A7 | Gene ID | 84068 |
| Gene name | solute carrier family 10 member 7 | |
| Gene Alias | C4orf13 | |
| Cytomap | 4q31.22 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q0GE19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84068 | SLC10A7 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.21e-07 | -4.07e-01 | 0.0155 |
| 84068 | SLC10A7 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.86e-06 | -4.18e-01 | 0.096 |
| 84068 | SLC10A7 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.08e-02 | -3.92e-01 | 0.0338 |
| 84068 | SLC10A7 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.44e-07 | -3.67e-01 | 0.0674 |
| 84068 | SLC10A7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.98e-04 | -3.23e-01 | 0.294 |
| 84068 | SLC10A7 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.97e-02 | -4.86e-01 | 0.2585 |
| 84068 | SLC10A7 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.13e-16 | -4.95e-01 | 0.3005 |
| 84068 | SLC10A7 | A015-C-203 | Human | Colorectum | FAP | 3.38e-21 | -4.24e-01 | -0.1294 |
| 84068 | SLC10A7 | A015-C-204 | Human | Colorectum | FAP | 5.51e-04 | -3.23e-01 | -0.0228 |
| 84068 | SLC10A7 | A002-C-201 | Human | Colorectum | FAP | 2.89e-08 | -3.28e-01 | 0.0324 |
| 84068 | SLC10A7 | A002-C-203 | Human | Colorectum | FAP | 1.68e-02 | -1.11e-01 | 0.2786 |
| 84068 | SLC10A7 | A001-C-119 | Human | Colorectum | FAP | 1.06e-08 | -5.03e-01 | -0.1557 |
| 84068 | SLC10A7 | A001-C-108 | Human | Colorectum | FAP | 6.82e-13 | -3.19e-01 | -0.0272 |
| 84068 | SLC10A7 | A002-C-205 | Human | Colorectum | FAP | 3.64e-13 | -3.69e-01 | -0.1236 |
| 84068 | SLC10A7 | A001-C-104 | Human | Colorectum | FAP | 7.77e-05 | -3.29e-01 | 0.0184 |
| 84068 | SLC10A7 | A015-C-005 | Human | Colorectum | FAP | 1.07e-02 | -2.43e-01 | -0.0336 |
| 84068 | SLC10A7 | A015-C-006 | Human | Colorectum | FAP | 3.00e-11 | -4.84e-01 | -0.0994 |
| 84068 | SLC10A7 | A015-C-106 | Human | Colorectum | FAP | 2.65e-08 | -3.16e-01 | -0.0511 |
| 84068 | SLC10A7 | A002-C-114 | Human | Colorectum | FAP | 1.78e-09 | -3.88e-01 | -0.1561 |
| 84068 | SLC10A7 | A015-C-104 | Human | Colorectum | FAP | 5.90e-24 | -4.24e-01 | -0.1899 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:00481932 | Colorectum | MSS | Golgi vesicle transport | 101/3467 | 296/18723 | 9.09e-11 | 9.77e-09 | 101 |
| GO:00067902 | Colorectum | MSS | sulfur compound metabolic process | 85/3467 | 339/18723 | 1.52e-03 | 1.39e-02 | 85 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:00481934 | Colorectum | FAP | Golgi vesicle transport | 77/2622 | 296/18723 | 2.86e-08 | 2.62e-06 | 77 |
| GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
| GO:0006814 | Colorectum | FAP | sodium ion transport | 54/2622 | 245/18723 | 3.98e-04 | 4.85e-03 | 54 |
| GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
| GO:00481935 | Colorectum | CRC | Golgi vesicle transport | 59/2078 | 296/18723 | 5.47e-06 | 2.17e-04 | 59 |
| GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
| GO:0060348 | Colorectum | CRC | bone development | 37/2078 | 205/18723 | 1.96e-03 | 1.96e-02 | 37 |
| GO:00068692 | Colorectum | CRC | lipid transport | 63/2078 | 398/18723 | 2.36e-03 | 2.26e-02 | 63 |
| GO:00108763 | Colorectum | CRC | lipid localization | 68/2078 | 448/18723 | 4.60e-03 | 3.58e-02 | 68 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC10A7 | SNV | Missense_Mutation | c.233N>C | p.Ile78Thr | p.I78T | Q0GE19 | protein_coding | tolerated(0.23) | benign(0.003) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC10A7 | deletion | Frame_Shift_Del | novel | c.293delN | p.Thr98AsnfsTer8 | p.T98Nfs*8 | Q0GE19 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SLC10A7 | SNV | Missense_Mutation | rs201032148 | c.782C>T | p.Ser261Leu | p.S261L | Q0GE19 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC10A7 | SNV | Missense_Mutation | novel | c.1072N>A | p.His358Asn | p.H358N | Q0GE19 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-C5-A8YT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SLC10A7 | SNV | Missense_Mutation | rs201032148 | c.782N>T | p.Ser261Leu | p.S261L | Q0GE19 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SLC10A7 | SNV | Missense_Mutation | rs201032148 | c.782N>T | p.Ser261Leu | p.S261L | Q0GE19 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SLC10A7 | SNV | Missense_Mutation | novel | c.1015N>T | p.Pro339Ser | p.P339S | Q0GE19 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC10A7 | SNV | Missense_Mutation | rs201032148 | c.782N>T | p.Ser261Leu | p.S261L | Q0GE19 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC10A7 | SNV | Missense_Mutation | novel | c.763N>G | p.Phe255Val | p.F255V | Q0GE19 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC10A7 | SNV | Missense_Mutation | novel | c.220N>A | p.Leu74Ile | p.L74I | Q0GE19 | protein_coding | tolerated(0.27) | benign(0.038) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |